Should I get a comprehensive genomic panel for Neuroendocrine Tumors

Should You Get a Comprehensive Genomic Panel for Neuroendocrine Tumors?

The short answer: Yes, genomic testing is generally recommended for neuroendocrine tumors (NETs), but the specific type and timing depends on your individual situation.

What the Guidelines Say

According to the NCCN Guidelines for Neuroendocrine and Adrenal Tumors, comprehensive molecular profiling can provide important information for:

• Identifying treatment options - Certain genetic mutations (like MTOR, CDKN1B, and others) may predict which targeted therapies could work for your tumor
• Predicting prognosis - Some mutations are associated with more aggressive disease
• Detecting inherited cancer risks - About 5% of neuroendocrine tumors are linked to hereditary syndromes (like MEN1 or VHL mutations) that affect your family members

Key Biomarkers Doctors Look For

The NCCN Guidelines highlight several important markers in NETs:

Chromogranin A (CgA) - A blood test that helps monitor disease progression, though it has limitations (can be elevated by certain medications or kidney disease)

NETest - A newer blood-based test that analyzes multiple genes and may be more accurate than traditional markers for:

• Detecting residual disease after surgery
• Predicting treatment response
• Monitoring for recurrence

Tumor-specific mutations - Including MTOR pathway alterations, CDKN1B changes, and others that may guide targeted therapy selection

When Timing Matters

At diagnosis: Comprehensive testing is most useful when you're planning initial treatment, especially if surgery or systemic therapy is being considered.

At progression: If your disease progresses or you need new treatment options, updated testing may reveal new mutations that have emerged.

Important Considerations

⚠️ Variants of Unknown Significance (VUS) - Sometimes genomic testing identifies mutations that doctors can't yet interpret. This can be frustrating, but it doesn't mean the test wasn't valuable—it means more research is needed.

Testing consistency: Different labs may report results differently, so if you're getting second opinions, make sure your oncologist is comparing results from the same tumor tissue when possible.

Questions to Ask Your Oncologist

1. Do you recommend comprehensive genomic testing for my specific type of NET? (The answer may differ for pancreatic NETs vs. small bowel NETs vs. other types)

2. Which specific mutations are most actionable for treatment in my case? (Focus on mutations that actually change your treatment options)

3. Should we test now or wait until we have more information about my disease?

4. If we find variants of unknown significance, what's the plan for interpreting them? (Some labs offer functional testing or consultation with specialists)

5. Will you compare results across different testing platforms if I get multiple tests?

6. Should my family members be tested for inherited mutations? (Relevant if you have MEN1, VHL, or other hereditary syndromes)

The Bottom Line

Comprehensive genomic testing is a valuable tool for neuroendocrine tumors and is increasingly recommended by major cancer centers. However, the real value comes from having an oncologist who can interpret the results and connect them to actual treatment options for YOUR specific situation.

According to the NCCN Guidelines, the decision should be individualized based on your tumor type, stage, and treatment goals—not just done routinely without a clear plan for how to use the information.

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.